LYSOGENE news, videos and press releases
For more news please use our advanced search feature.
LYSOGENE - More news...
LYSOGENE - More news...
- Lysogene Announces the Conversion of the Reorganization Proceedings into Judicial Liquidation and its Delisting
- Lysogene: Hearing Scheduled on May 23, 2023 on the Possible Opening of Judicial Liquidation Proceedings
- Lysogene Announces Postponement of 2022 Financial Results Release
- Lysogene announces that no takeover offer was filed
- Lysogene Announces the Extension of Deadline for the Submission of Offers
- Lysogene Announces the Extension of Deadline for the Submission of Offers
- Lysogene Appoints Côme de La Tour du Pin as Chief Financial Officer
- Lysogene: Conversion of the Safeguard Proceedings Into Reorganization Proceedings
- Lysogene: Launch of a Process to Find Buyers or Investors and Request for Conversion of Safeguard Proceedings Into Reorganization Proceedings
- Lysogene announces the opening of a safeguard proceeding
- Lysogene Announces the Request for the Opening of a Safeguard Proceeding
- Lysogene Provides Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study
- Lysogene Provides Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study
- Lysogene to Provide Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study and Host Webcast on Wednesday, November 23, 2022
- Lysogene Reports its Cash Position as of 30 September 2022
- Lysogene Reports First Half 2022 Financial Results
- Lysogene: New Board of Directors
- Lysogene Reports its Cash Position as of 30 June 2022
- Half-Year Report on the Liquidity Contract Signed by Lysogene With Kepler Cheuvreux
- Lysogene Provides Additional Update on AAVance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in children with MPS IIIA
- Lysogene Releases Results From June 24, 2022, Ordinary and Extraordinary Annual General Meeting
- Lysogene Provides Clinical Update on AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPS IIIA at the 25th Annual ASGCT Meeting
- Lysogene Provides Clinical Update on AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPS IIIA at the 25th Annual ASGCT Meeting
- Lysogene Reports its Cash Position as of 31 March 2022
- Lysogene Publishes Positive Preliminary Preclinical Results in the Treatment of Fragile X Syndrome
- Lysogene Announces Filing of 2021 Universal Registration Document
- Lysogene Enters into an Exclusive Worldwide License Agreement with Yeda, the Commercial Arm of the Weizmann Institute of Science, for a Novel Gene Therapy Candidate for Neuronopathic Gaucher Disease and Parkinson Disease with GBA1 Mutations
- Lysogene Reports Full Year 2021 Financial Results
- Lysogene Provides Update on Efficacy, Safety and Timelines of the AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPSIIIA
- Lysogene Reports Additional Positive Biomarker Data With LYS-SAF302 and Favorable Safety Data With LYS-GM101 Presented at the WORLDSymposium™ 2022
